Results 231 to 240 of about 414,323 (331)

When Autoimmunity Meets Malignancy: A Rare Case of Concomitant Systemic Lupus and Multiple Myeloma. [PDF]

open access: yesClin Case Rep
Ratsimbazafy SJN   +7 more
europepmc   +1 more source

Burden of haematological malignancies among children, adolescents and young adults: Global and high‐income region insights from the GBD 2021 study

open access: yesBritish Journal of Haematology, EarlyView.
Summary This study provides a comprehensive assessment of haematological malignancies among children, adolescents and young adults aged 0–24 years, using data from the Global Burden of Disease 2021 across 204 countries from 1990 to 2021. We found that global incidence and prevalence remained relatively stable, with approximately 150 000 new cases and ...
Shujuan Xu   +4 more
wiley   +1 more source

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

open access: yesHaematologica, 2017
Sharmilan Thanendrarajan   +20 more
doaj   +1 more source

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study. [PDF]

open access: yesHemasphere
Beksac M   +18 more
europepmc   +1 more source

Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review

open access: yesBritish Journal of Haematology, EarlyView.
This systematic review of 55 trials reveals significant inconsistency in defining transplant ineligibility for multiple myeloma. Arbitrary age cut‐offs predominantly drive exclusion, while validated frailty tools and specific comorbidities are frequently underutilized.
Karun Neupane   +15 more
wiley   +1 more source

Super-resolution binding activated localization microscopy through reversible change of DNA conformation [PDF]

open access: yes, 2018
Aleksander Szczurek   +5 more
core   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy